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Acute pancreatitis as a complication of
percutaneous mechanical thrombectomy
Michael Lebow, MD, David Cassada, MD, Oscar Grandas, MD, Scott Stevens, MD,
Mitchell Goldman, MD, and Michael Freeman, MD, Knoxville, Tenn
Percutaneous mechanical thrombectomy can be an effective procedure performed with low morbidity. We have observed
clinically significant pancreatitis after successful clot extraction by percutaneous thrombectomy. Pancreatitis developed
postoperatively in four patients who underwent thrombectomy at our hospital. Each patient experienced abdominal
symptoms with serologic and radiographic evidence of pancreatitis<24 hours after thrombectomy. The presence of renal
failure and extensive clot degradation seemed to be related. Two of the patients underwent surgery that potentially could
have been avoided had the etiology of pancreatitis been known preoperatively. ( J Vasc Surg 2007;46:366-8.)In recent years, percutaneous mechanical thrombec-
tomy (PMT) devices have been used with increasing fre-
quency because of their low morbidity, ease of use, and
efficacy. Several devices have been approved by the United
States Food and Drug Administration, primarily for use in
hemodialysis grafts and arteriovenous fistulas. The Angio-
Jet rheolytic catheter (Possis Medical, Minneapolis, Minn)
is one of the more versatile devices and has proven to be
effective in the treatment of thrombosed hemodialysis
grafts, deep venous thrombosis, and acute lower extremity
ischemia.1-3
The AngioJet rheolytic system is a dual-lumen catheter
that serves both a delivery and exhaust function. One
lumen carries highly pressurized saline that is forcefully
ejected at 10,000 to 15,000 psi to simultaneously lyse
thrombus and create a pressure vacuum that draws clot
fragments into the catheter where they can be evacuated by
an exhaust lumen. This mechanism is based on the Venturi
principal, which is that a negative pressure is produced by a
fluid stream passing through a constriction and increasing
velocity. The net effect is a hydrodynamic vortex around
the tip of the catheter and the lysis of thrombus by hydro-
dynamic forces, and with this method, the rheolytic system
is purported to be isovolumetric.
Several studies have documented the effectiveness and
low morbidity of rheolytic thrombectomy. Potential com-
plications include vessel perforation and dissection as well
as distal embolization of clot fragments. Intravascular he-
molysis, with subsequent myoglobinuria, and renal insuffi-
ciency have also been reported.1,4 Vesely et al2 attributed a
fourfold increase in plasma free hemoglobin after AngioJet
thrombectomy of clotted dialysis grafts to intravascular
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366hemolysis. In addition, bradycardia and heart block have
been attributed to the release of adenosine from hemolyzed
blood.5 To date, despite a well-documented association
between intravascular hemolysis and acute pancreatitis, few
reports documenting pancreatitis as a complication of rheo-
lytic thrombectomy have been published.4,6
We reviewed the records of patients who underwent
percutaneous thrombectomy performed at out institution
between May 01, 2004, and Jan 31, 2006. PMT patients
were identified by manually reviewing our endovascular
suite procedure log. Patients with pancreatitis were cap-
tured using our hospital coding system to identify patients
who had pancreatitis while admitted under the care of a
vascular surgeon. The charts of patients with both designa-
tors were reviewed, and patients who presented with ab-
dominal pain with serologic and radiographic signs of acute
pancreatitis 48 hours of PMT were included in this
report. At our institution, AngioJet rheolytic thrombec-
tomy was used exclusively during the study period. The
medical records of patients who met inclusion criteria were
reviewed, and periprocedural details, comorbidities, medi-
cations, and laboratory data were analyzed.
CASE REPORT
Four patients (mean age, 47  14 years) presented with
pancreatitis after PMT. All four were men and without a history
of pancreatitis. None were receiving medications associated with
pancreatitis. The vessels treated included two iliac arteries for lower
extremity ischemia, one innominate and subclavian vein for facial
swelling, and a thrombosed arteriovenous graft. During each treat-
ment event, urokinase (250,000 U) was administered within the
pulsed solution and left in place for 10 minutes before PMT.
The patients with innominate vein and arteriovenous graft
occlusions were dialysis-dependent, and one of the patients with
iliac artery occlusion had chronic renal insufficiency (creatinine,
1.6 mg/dL). The remaining patient with an iliac artery occlusion
had normal renal function. The hematocrit of patients who pre-
sented with pancreatitis decreased an average of 10.45 points after
the procedure (Table). The charts of 12 randomly selected patients
without clinically apparent pancreatitis were also reviewed, and an
average hematocrit drop of 3.31 was found in this group. The
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flects prolonged thrombectomy procedures in those patients.
Each patient who presented with pancreatitis experienced
symptoms 24 hours of PMT. The mean postprocedure amylase
and lipase levels were 1649 U/L and 1584 U/L, respectively.
Computerized tomography (CT) was diagnostic for acute pancre-
atitis in three of the four patients; in the fourth patient, the CT
imaging showed inflammatory changes in the greater omentum
and right mesocolon. This patient underwent exploratory laparot-
omy for an acute abdomen, and pancreatic inflammation and
saponification were identified. Another patient underwent laparo-
scopic cholecystectomy during the same admission for presumed
biliary pancreatitis where a normal gallbladder was found. The
remaining two patients recovered 72 hours with conservative
management consisting of bowel rest, pain control, and intrave-
nous fluids. No complications occurred in the patients because of
the pancreatitis.
DISCUSSION
The association between intravascular hemolysis and
acute pancreatitis is well described. Medical conditions
such as autoimmune hemolysis, glucose-6-phosphate de-
hydrogenase deficiency, malaria, and Wilson disease have
been shown to have as high as a 25% risk of acute pancre-
atitis after episodes of massive hemolysis.7 Symptoms typi-
cally symptoms start within a day of the hemolytic event.
Pancreatitis is also a well-documented complication of me-
chanical hemolysis resulting from kinked dialysis cathe-
ters.8-10 No association has been reported between throm-
bolysis with urokinase and pancreatitis.
Pancreatitis as a result of hemolysis is caused by the
release of free hemoglobin. Normally, carriers such as he-
mopexin take up unbound hemoglobin, but hemolysis can
overwhelm this clearing process and allow hemoglobin to
persist in the bloodstream.11 Hemoglobin has been impli-
cated as an activator of several components of the inflam-
matory response. It can recruit and activate neutrophils,
causing them to undergo cytoskeletal reorganization, de-
granulation, and produce reactive oxygen species.12 Ele-
vated hemoglobin levels also cause the upregulation of -2
microglobulin, an acute-phase protein.13 In addition, he-
moglobin may affect the microvasculature of the pancreas
Table. Patients with pancreatitis
Patient 1 Patient 2 Patient 3 Patient 4
Age/sex 61/M 50/M 50/M 26/M
Vessel Iliac artery Iliac arteries Innominate AV graft
ESRD – –  
Alcohol abuse –  – –
Creatinine 1.6 1.1 8.9 8.9
 Hematocrit 10.2 12.3 8.5 11.3
Triglycerides 179 83 36 224
Calcium 9.8 9.4 10.1 10.2
Amylase 2761 522 1701 1612
Lipase 2280 538 1156 236
ESRD, End-stage renal disease; AV, arteriovenous.by promoting intravascular coagulation and causing vaso-constriction by inhibiting endothelium-derived relaxing
factor.11 Finally, the remnants of hemoglobin degradation
have been implicated in oxygen free radical formation,
which causes cell injury.11
The risk of pancreatitis developing is also likely related
to several factors, including thrombus burden, the amount
of flow in the treated vessel, the length of catheter activa-
tion time, and the patient’s renal function. Pancreatitis
developed in four patients in our study. Although 60% of
the PMTs in our study period were performed on renal
failure patients with thrombosed arteriovenous grafts, pan-
creatitis developed in only one of these patients.
One technical factor not previously emphasized as a risk
for pancreatitis is the use of the catheter in flowing blood.
The evacuation of byproducts relies on the negative pres-
sure produced by the Venturi effect, which may be coun-
teracted by adjacent blood flow. It is our standard practice
to thrombectomize the venous side of arteriovenous grafts
before the arterial limb to avoid embolizing thrombus into
the distal brachial artery. As a result, there is no flow in the
graft during thrombectomy. This may explain the lower
incidence of pancreatitis in arteriovenous thrombectomy
despite the relatively large thrombus burden and renal
failure in these patients.
Long AngioJet activation periods lyse more red blood
cells, release more byproducts than brief episodes of PMT,
and contribute to myoglobinuria and pancreatitis.4 In the
two previous reports, as in our study, pancreatitis devel-
oped in patients who had PMT of central vessels and large
thrombus burdens. The nine reported cases (our four in-
cluded) occurred after PMT of the superior vena cava/
innominate (n  2), iliac artery or vein (n  5), polytetra-
fluoroethylene femoropopliteal graft (n  1), and
arteriovenous graft (n  1).
Current recommendations for use of the AngioJet
catheter are to limit run time to 4minutes in flowing vessels
and 8 minutes in thrombus. The deployment of a distal
occlusion balloon could theoretically limit the systemic
spread of hemolytic byproducts by halting blood flow and
lower the incidence of post-PMT pancreatitis in high-risk
patients and procedures.
During the same period, an additional 261 patients
underwent PMT and clinically apparent pancreatitis did not
develop. Pancreatic enzymes were not routinely checked,
so we cannot say if these patients had subclinical pancreatic
inflammation. A limitation to our study is the lack of data
pertaining to pump run times, volume of effluent, urine
myoglobin, and plasma free hemoglobin. As a result, we
were unable to quantify hemolysis.
CONCLUSION
Studies emphasizing the technical aspects of PMT in
addition to patient comorbidities would be helpful in de-
termining the risk factors for post-PMT pancreatitis. In the
meantime, physicians should be aware of pancreatitis after
PMT and evaluate pancreatic enzyme levels in the setting of
unexplained abdominal pain after PMT. Surgeons are fa-
miliar with treating myoglobinuria with hydration, diuret-
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these after extensive thrombectomies. Furthermore, recog-
nition of pancreatitis as a complication may reduce the
number of unnecessary tests and procedures performed for
the work-up of acute abdominal pain that occurs after these
procedures.
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